p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma

[1]  M. Takata,et al.  Comparison of genetic profiles between primary melanomas and their metastases reveals genetic alterations and clonal evolution during progression. , 1998, The Journal of investigative dermatology.

[2]  G. Walker,et al.  Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets , 1998, Genes, chromosomes & cancer.

[3]  J. Herman,et al.  Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. , 1998, Cancer research.

[4]  V. Gouyer,et al.  Mechanisms of p16INK4A inactivation in non small-cell lung cancers , 1998, Oncogene.

[5]  W. Farrell,et al.  Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. , 1997, Cancer research.

[6]  M. Broggini,et al.  Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. , 1997, British Journal of Cancer.

[7]  G. Chenevix-Trench,et al.  Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours , 1997, International journal of cancer.

[8]  B. Leggett,et al.  Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population , 1997, Hepatology.

[9]  William D. Foulkes,et al.  The CDKN2A (p16) Gene and Human Cancer , 1997, Molecular medicine.

[10]  K. Ichimura,et al.  Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. , 1997, British journal of cancer.

[11]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  E. Healy,et al.  Infrequent mutation of p16INK4 in sporadic melanoma. , 1996, The Journal of investigative dermatology.

[13]  C. Shields,et al.  Deletion mapping of chromosome region 9p21‐p22 surrounding the CDKN2 locus in melanoma , 1996, International journal of cancer.

[14]  E. Hovig,et al.  CDKN2A (p16INK4A) somatic and germline mutations , 1996, Human mutation.

[15]  R. Beart,et al.  Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. , 1995, Cancer research.

[16]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[17]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[18]  E. Healy,et al.  Loss of heterozygosity in sporadic primary cutaneous melanoma , 1995, Genes, chromosomes & cancer.

[19]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[20]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[21]  M H Skolnick,et al.  Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  N. Hayward,et al.  Microsatellite instability in melanoma. , 1994, Melanoma research.

[23]  N. Hayward,et al.  Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma , 1994, International journal of cancer.

[24]  Cécile Fizames,et al.  The 1993–94 Généthon human genetic linkage map , 1994, Nature Genetics.

[25]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[26]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[27]  J. Kirkwood,et al.  Homozygous deletions within human chromosome band 9p21 in melanoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Ferrone,et al.  Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. , 1991, Cancer research.

[29]  D. Housman,et al.  Genetics of melanoma. , 1990, Cancer surveys.

[30]  W. Coleman,et al.  Acral Lentiginous Melanoma: A Clinicopathologic Entity , 1982, Annals of surgery.